Recipes and Stuff

Recipes, Food, Health, Lifestyle, and News

Menu
  • Industry News
  • Cakes
  • Soups
  • Vegan lifestyle
  • Indian recipes
  • Desserts
  • Blog
  • About
Menu

MaxCyte Signs Strategic Platform License with Curamys for the Treatment of Rare Intractable Diseases

Posted on December 5, 2022December 5, 2022 by Kiran

SEOUL, SOUTH KOREA: MaxCyte Inc. (LSE: MXCT), a cell-engineering focused company, and Curamys, a South Korean biotechnology company announced the signing of a strategic platform license (SPL).

Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.

Curamys is focused on developing treatments for genetic and degenerative diseases through its specialized cell fusion technology, based on the concept that apoptotic or dying cells can be regenerated by fusing them with healthy normal cells. Cell fusion technology can function as a form of gene therapy when the normal copies of genes existing in treatment cells are transferred to dying cells, resulting in the development of a treatments for genetic and rare intractable diseases at the cellular level.

“A recent report estimates that there are more than 10,000 distinct rare diseases affecting 400 million people around the world,” said Doug Doerfler, President and CEO of MaxCyte. “Many of these diseases, like ALS and DMD, have few or no treatments. We are honored to support Curamys’ efforts to develop its cell-fusion technology for novel cell-based treatments that provide hope and new options to patients and their families.”

“At Curamys, our goal is to use cell fusion-based technologies to transform the biomedical sciences by helping to identify genetic factors contributing to numerous rare diseases with unknown medical causes,” said Dr. Jung Joon Sung, CEO of Curamys. “MaxCyte’s Platform will enable us to advance this technology so we can expand our global reach and ultimately, help more patients living with rare diseases.”

MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Curamys is MaxCyte’s 18th SPL overall, which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Advanced Medical Solutions Group has acquired Connexicon Medical Limited
  • Scancell Holdings appoints Dr Jean-Michel Cosséry as Non-Executive Chairman
  • Actinogen Medical appoints Dr Dana Hilt as Chief Medical Officer
  • Adherium launches new Interactive Investor Hub
  • Mayfair Equity Partners offers to acquire Seraphine Group for 30 pence/share

Recent Comments

  1. 먹튀사이트 on Ancient Chinese coastal city is a desirable destination for foodies
  2. 먹튀검증업체 on Bayer strengthens Government & Industry Affairs group in Key U.S. market
  3. 먹튀검증업체 on Evgen Pharma expands collaboration with Manchester Breast Centre
  4. Business Ideas UK on Ancient Chinese coastal city is a desirable destination for foodies
  5. Business Ideas UK on AstraZeneca and Neurimmune close deal for NI006

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022

Categories

  • Blog
  • Cakes
  • Desserts
  • Indian recipes
  • Industry News
  • Recipes
  • Soups
  • Trending Beverages
  • Uncategorized
  • Vegan lifestyle
©2023 Recipes and Stuff | Theme by SuperbThemes